(2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]butanoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-2-[[4-[(2-amino-4-oxo-3H-pteridin-6-yl)methylamino]benzoyl]amino]butanoic acid
• 化学式: C₁₈H₁₉N₇O₄
• 分子量: 397.4
• InChiKey: VAEFPYXPGBDXAT-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  172
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• NOVEL SELF-REACTIVE ARMS AND PRODRUGS COMPRISING SAME
  申请人：Papot Sebastien

  公开号：US20130144045A1

  公开（公告）日：2013-06-06

  The present invention relates to a compound of general formula (I): in which: X is OH, NH 2 , NHOH or RNH, where R may be a linear or branched, saturated or unsaturated, C1-C10 alkyl radical, Y is H, or an electron-withdrawing group, in particular selected from NO 2 , CF 3 or a halogen, R1 and R2 are H or a linear or branched, saturated or unsaturated, C1-C10 alkyl radical, F is a reactive functional group that can be activated by click chemistry.

  本发明涉及一种通式（I）的化合物： 其中，X为OH，NH2，NHOH或RNH，其中R可能是线性或支链，饱和或不饱和的C1-C10烷基基团， Y为H或电子提取基团，特别是选择自NO2，CF3或卤素， R1和R2为H或线性或支链，饱和或不饱和的C1-C10烷基基团， F是可以通过点击化学激活的反应性功能基团。
• ENZYME INHIBITING COMPOUNDS
  申请人：Roberts Michael J.

  公开号：US20110112126A1

  公开（公告）日：2011-05-12

  The present invention is directed to compounds that are specifically structured to provide enzyme inhibition. In specific embodiments, the enzyme inhibiting compounds exhibit antifolate activity. Particularly, the inventive compounds are formed of an antifolate residue that is active in inhibiting one or more of TS, DHFR, GAR, FPGS, and AICAR Tfase. The enzyme inhibiting compounds are useful in a variety of methods of treatment, including treating abnormal cell proliferation and treating inflammation.

  本发明涉及一种具有特定结构以提供酶抑制作用的化合物。在具体实施例中，这些酶抑制化合物表现出抗叶酸活性。特别地，本发明的化合物由一个抗叶酸残基形成，该残基在抑制TS、DHFR、GAR、FPGS和AICAR Tfase中的一个或多个方面具有活性。这些酶抑制化合物在多种治疗方法中有用，包括治疗异常细胞增殖和治疗炎症。
• CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS
  申请人：Leamon Christopher Paul

  公开号：US20100323973A1

  公开（公告）日：2010-12-23

  Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.

  本文描述了一种使用细胞受体结合药物递送共轭物质的组合物和方法，其中包含亲水性空间连接剂，用于成像、诊断和/或治疗由致病细胞群体引起的疾病和疾病状态的靶向药物递送。
• METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE
  申请人：Leamon Christopher Paul

  公开号：US20100104626A1

  公开（公告）日：2010-04-29

  The invention relates to a method for diagnosing a kidney disease state. The method comprises the steps of administering to a patient a composition comprising a conjugate or complex of the general formula V-L-D where the group V comprises a vitamin receptor binding ligand that binds to kidney proximal tubule cells and the group D comprises a diagnostic marker, and diagnosing the kidney disease state. The invention also relates to a method for treating a kidney disease state. The method comprises the steps of administering to a patient suffering from the disease state an effective amount of a composition comprising a conjugate or complex of the general formula V-L-D where the group V comprises a vitamin receptor binding ligand that binds to kidney proximal tubule cells and the group D comprises an antigen, a cytotoxin, or a cell growth inhibitor, and eliminating the disease state.
• STABLE CRYSTALLINE SALTS OF ANTIFOLATE COMPOUNDS
  申请人：Pimplaskar Harish K.

  公开号：US20110124650A1

  公开（公告）日：2011-05-26

  The present invention provides stable crystalline polymorphic forms of antifolate compounds, particularly (S)-2-4-[2-(2,4-diamino-quinazolin-6-yl)-ethyl]-benzoylamino}-4-methylene-pentanedioic acid, dipotassium salt, and methods of preparation thereof The polymorphs may be in the form of hydrates. The invention further provides pharmaceutical compositions comprising the polymorphs and methods of treatment using the polymorphs. The polymorphs are useful in the treatment of multiple conditions, including abnormal cell proliferation, inflammatory diseases, asthma, and arthritis, and the polymorphs may be administered alone in or combination with on or more further active agents.